Company
Resistell AG
Incorporated
April 2018
Headquarter
Muttenz
Support
Revolutionary alternative for antibiotic susceptibility test
Resistell is revolutionizing Antibiotic Susceptibility Testing (AST) with the world’s fastest platform. Our CE IVD-certified AST for bloodstream infections has been validated in two clinical studies with over 500 patient samples, achieving more than 95% accuracy. The current version of our Phenotech device delivers ultra-rapid phenotypic AST results in just 2 hours—a speed unmatched by any other technology. To date, we have secured CHF 17 million in equity and CHF 4 million in grants. We are now raising funds for high-throughput device, leveraging our cutting-edge, highly de-risked nanomotion technology. The prototype of a high-throughput device, developed with an industrial partner, is ready for further advancement.
